ITOS - iTeos Therapeutics, Inc.
IEX Last Trade
7.375
0.015 0.203%
Share volume: 8,713
Last Updated: Thu 26 Dec 2024 08:30:22 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$7.36
0.02
0.20%
Fundamental analysis
12%
Profitability
10%
Dept financing
4%
Liquidity
75%
Performance
0%
Performance
5 Days
1.63%
1 Month
-8.79%
3 Months
-26.51%
6 Months
-50.33%
1 Year
-31.15%
2 Year
-60.64%
Key data
Stock price
$7.38
DAY RANGE
$7.26 - $7.46
52 WEEK RANGE
$7.44 - $18.75
52 WEEK CHANGE
-$32.34
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Michel Detheux
Region: US
Website: iteostherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: iteostherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Iteos Therapeutics, Inc. engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials. EOS-448 is an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains.
Recent news